Liebhoff, Anna-Maria http://orcid.org/0000-0002-0134-9672
Venkataraman, Thiagarajan
Morgenlander, William R. http://orcid.org/0000-0001-7205-3732
Na, Miso http://orcid.org/0009-0000-3700-859X
Kula, Tomasz http://orcid.org/0000-0002-6458-9833
Waugh, Kathleen
Morrison, Charles
Rewers, Marian http://orcid.org/0000-0003-3829-9207
Longman, Randy
Round, June http://orcid.org/0000-0002-7158-9874
Elledge, Stephen http://orcid.org/0000-0001-7923-6283
Ruczinski, Ingo
Langmead, Ben
Larman, H. Benjamin http://orcid.org/0000-0001-7863-196X
Article History
Received: 14 July 2023
Accepted: 26 January 2024
First Online: 21 February 2024
Competing interests
: HBL and SE are inventors on an issued patent (US20160320406A) filed by Brigham and Women’s Hospital that covers the use of PhIP-Seq for antiviral antibody detection; HBL is a founder of Portal Bioscience, Alchemab, and Infinity Bio. TK is a founder of TSCAN Therapeutics. SE is a founder of TSCAN Therapeutics, MAZE Therapeutics and Mirimus, serves on the scientific advisory boards of Homology Medicines, MAZE Therapeutics and TSCAN Therapeutics, and is an advisor for MPM Capital, none of which affect this work. The remaining authors declare no competing interests.